Pooled data from phase III trials confirms Motif Bio’s iclaprim drug is safer than gold standard

04:09 EDT 11 Jun 2018 | Proactive Investors

Pooled data from the REVIVE-1 and REVIVE-2 trials confirmed that iclaprim is non-inferior to vancomycin and significantly safer

More From BioPortfolio on "Pooled data from phase III trials confirms Motif Bio’s iclaprim drug is safer than gold standard"